Co-Inventors
Shen, Chen-Hsiang
Reveiz, Mateo
Kwong, Peter
Chauang, Gwo-yu
Seder, Robert
Francica, Joseph
Xu, Kai
Tripathi, Prabhanshu
Rawi, Reda
Applications
Vaccines
Therapeutics
Research Materials
The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities. Through an innovative mouse model using B cells with the inferred germline version of CIS43, researchers have successfully identified and isolated potent CIS43 variants. These variants, produced via somatic hypermutation and epitope-contact residue optimization, offer a 3-5 fold increase in protection over the original CIS43. This progress marks a significant stride towards a more effective prophylactic strategy against malaria, with potential implications for vaccine development and antibody-based interventions.
Commercial Applications
The CIS43 antibody variants stand at the forefront of malaria intervention, offering a substantial competitive advantage with their markedly improved protective efficacy against the Plasmodium falciparum circumsporozoite protein. The leap in efficacy is achieved through informed enhancements in the antibodies' binding affinity, a result of targeted somatic hypermutations—a feature that sets these variants apart from other prophylactic options. The refined specificity and enhanced potency could translate to longer-lasting immunity, lower dosages, and greater cost-effectiveness, all of which are critical factors in the global battle against malaria, particularly in regions where the disease burden is highest.
Competitive Advantages
The CIS43 antibody variants stand out in the competitive landscape of malaria prophylactics with their heightened efficacy—a 3-5 fold increase in malaria protection compared to the original antibody. This superior performance is rooted in the targeted somatic hypermutation and fine-tuning of epitope-contact residues, ensuring a robust immune response. The use of a novel mouse model that mimics the human immune response to the Plasmodium falciparum circumsporozoite protein further underscores the potential for these variants to transition smoothly from pre-clinical studies to human trials.
